AbbVie, Roche's Venclexta flops confirmatory trial in AML by Kyle Blankenship Monday, March 2, 2020 AbbVie and Roche were looking for a trial win to confirm blood cancer drug Venclexta's FDA approval in AML. Instead, the pair got a setback.
Daiichi, Glenmark, Takeda and more—FiercePharmaAsia by Angus Liu Friday, June 28, 2019 The FDA rejects Daiichi's quizarinib and Glenmark's Ryaltris; Takeda sets a deadline for its U.S. headquarters move; JLABS Shanghai launches.
Daiichi, Keytruda, Chi-Med and more—FiercePharmaAsia by Angus Liu Friday, April 5, 2019 Daiichi inks $6.9 billion ADC deal with AZ, appoints new CEO; Keytruda nabs first-line lung cancer nod in China.
Astellas pads Xospata lead with AML survival data by Carly Helfand Monday, April 1, 2019 Astellas is looking to snap up share with Xospata before an AML rival hits the scene, and new survival data could help speed that process along.
